Biomed Industries at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Biomed Industries takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on NA-831, with phase 2 evidence for a neurogenesis-based treatment of Alzheimer's disease and a broader theory linking neurodegenerative, metabolic and cardiovascular disease.

Organization	CTAD 2026 Attendance
Biomed Industries San Jose, California
biomedind.com Biotech Develops NA-831, an oral drug proposed to promote neurogenesis, for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease (P173) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke (P174) Other mechanisms and targets

Organization

CTAD 2026 Attendance

Biomed Industries

San Jose, California

biomedind.com

Biotech

Develops NA-831, an oral drug proposed to promote neurogenesis, for Alzheimer's disease.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer’s Disease (P173)

Other mechanisms and targets

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke (P174)

Other mechanisms and targets

Instantly find 20 buyers from Biomed Industries

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction